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Roboticsa b s t r a c t
The increasing use of zebrafish larvae for biomedical research applications is resulting in versatile models
for a variety of human diseases. These models exploit the optical transparency of zebrafish larvae and the
availability of a large genetic tool box. Here we present detailed protocols for the robotic injection of zeb-
rafish embryos at very high accuracy with a speed of up to 2000 embryos per hour. These protocols are
benchmarked for several applications: (1) the injection of DNA for obtaining transgenic animals, (2) the
injection of antisense morpholinos that can be used for gene knock-down, (3) the injection of microbes
for studying infectious disease, and (4) the injection of human cancer cells as a model for tumor
progression. We show examples of how the injected embryos can be screened at high-throughput level
using fluorescence analysis. Our methods open up new avenues for the use of zebrafish larvae for large
compound screens in the search for new medicines.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
The use of zebrafish as an animal model has an abundance of
applications in fundamental research in vertebrate development,
physiology and toxicology [4,11,37,78,79]. More recently, this
model has also been shown to be highly applicable for studies of
many types of disease [1,2,5,9,35,44,52,55,57,59–61,73–75]. The
benefits of the relatively small and transparent larvae for optical
imaging using transgenic fish lines expressing many colour
varieties of the GFP protein have been widely exploited in these
disease studies [1]. Currently the genetic tool box is comprised of
a large variety of gene knock-down or knock-out systems
[6,10,14,20,21,25,43,64]. Additionally many genomic-based tech-
niques such as RNA deep sequencing, metabolomics and proteo-
mics have been applied to zebrafish [17–19,40,42,45,53,54,
66,71,97]. A comparison of parallel deep RNA sequencing and
proteome analysis has been reported (Palmblad et al., submitted).The fact that the innate immune system of zebrafish is highly
similar to that of mammals and is already fully functional as
early as two days after fertilization makes zebrafish larvae
extremely useful for studies of diseases related to the immune
system [72,94]. Examples given below are studies of cancer pro-
gression and infectious diseases caused by many bacteria, fungi
or viruses.
1.1. Zebrafish microinjection and screening tools
Microinjection of zebrafish embryos is an essential technology
for the following applications:
 The generation of transgenic zebrafish lines.
 The generation of gene knock-out lines using zinc fingers or
TALEN technology.
 Gene knock-down using morpholinos, siRNA or antibodies.
 Overexpression of genes by injection of mRNA.
 The injection of tracer dyes or particles.
 Intraorganismal introduction of microbes in embryos or
larvae for infection studies.
 Transplantation of cells between embryos.
 Xenograft implantation of cells for cancer studies.
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the book: Essential Zebrafish Methods: Cell and Developmental
Biology [26]. More specifically for injection methods that can be
used for these applications we can refer to detailed descriptions
in four methodology compendia or books: (1) Zebrafish: Methods
and Protocols [51], (2) The zebrafish book, A guide for the labora-
tory use of zebrafish (Danio rerio), 5th edition [99] and (3) Methods
in Cell Biology issues 104 and 105 [27,28], which provide compre-
hensive laboratory protocols and reviews for recent zebrafish
methods related to disease models and chemical screens. Recently
also video enhanced protocols for zebrafish microinjection have
been published, for instance by Benard et al. [7], describing in de-
tail the application of microinjection of bacterial pathogens. In
brief, all methods use thin glass capillary needles to introduce
compounds or biological materials inside various parts of embryos
and larvae. In the embryonic and early larval stages the transpar-
ency and softness of the tissues warrants a high success rate of
the injection protocol. In contrast, injection in the later larval
stages is more difficult due to higher rigidity of tissue and can cur-
rently only be performed at relatively low throughput. For the first
four applications mentioned above, DNA, RNA or morpholinos can
be injected into the yolk of early stage embryos. Due to the rela-
tively large size of the yolk this offers a fast procedure for microin-
jection that even can be completely automated. Robotic injection
of zebrafish embryos using image recognition has been shown to
accurately deliver morpholinos at a throughput level of 25 consec-
utive injections per run of 2 min [98]. Recently an alternative ro-
botic injection method was shown to inject embryos at a speed
of 2000 per hour with a success rate of 99% [15]. This method
makes use of specially designed grids where embryos occupy the
hemi-spherical wells of an agarose cast in a centred and com-
pletely reproducible manner, with the cell mass always resting to
the side. In this paper we present further applications and detailed
methods for the use of this robotic injection system. We will also
provide examples of high-throughput screening of injected em-
bryos. Screening of zebrafish embryos can make use of the rapid
technical advances in high-throughput analysis methods for zebra-
fish embryos [1,33,47]. The COPAS XL (Complex Object Parametric
Analyzer and Sorter) system (Union Biometrica) can be used for
fluorescence imaging of zebrafish embryos at a throughput level
of 200 embryos per minute. This system has been designed for
the analysis, sorting and dispensing of objects up to 1.5 mm in
diameter based on size, optical density and fluorescence intensity.
A profiler option simultaneously detects and analyzes up to 8000
data points per object for each of the channels of extinction and
fluorescence, and includes advanced imaging options. The result-
ing profiles can be used to set parameters for zebrafish larvae to
be sorted in 96-wells plates. In this paper we describe software
to process the recorded data for further statistical analysis. Re-
cently a vertebrate automated screening technology (VAST) with
cellular-resolution and parallel animal processing has been re-
ported in which the screening throughput is limited only by the
image acquisition speed rather than by the fluidic or mechanical
processes [16,67]. In the near future we will also use this method-
ology for zebrafish high content image analysis aimed at disease
screening at high-throughput such as discussed below.
1.2. Applications of microinjection for studies of infectious disease
A growing list of pathogenic bacteria, filamentous fungi, yeasts,
microsporidia, helminths, trypanosomes and viruses has been used
for experimental infection studies in zebrafish, as detailed in sev-
eral recent reviews [12,23,24,46,57,58,65,73]. Bacterial pathogens
have been tested most frequently, as discussed by Meijer and Spa-
ink [57] who present an overview of over 30 bacterial species for
which disease studies in zebrafish have been published. Inaddition, zebrafish larvae have also been used to study the effects
of a bacterial strains that normally do not cause a disease, Staphy-
lococcus epidermidis, for the purpose of studying the effects of fac-
tors such as medical implant materials on defence mechanisms
against commensal bacteria [97]. One of the most successful zebra-
fish disease models is the indirect study of human tuberculosis via
the infection of zebrafish embryos with Mycobacterium marinum,
as recently reviewed by Tobin, May and Wheeler [91]. The studies
of M. marinum infection have already led to the clarification of
many important processes in the life cycle of tuberculosis infec-
tion, in particular those underlying the mechanisms of granuloma
formation in which the bacteria proliferate in macrophages [8,92].
The context of the embryo’s developing immune system makes it
possible to study the contribution of different immune cell types
to disease progression already at 1–2 days post fertilization, when
functional macrophages and neutrophil develop. Furthermore, due
to the clear temporal separation of innate immunity from adaptive
responses, zebrafish larvae are particularly useful for dissecting the
innate host factors involved in pathology. Recent studies have
underscored the remarkable similarity of the zebrafish and human
immune systems, which is important for biomedical applications
[94]. Since conserved pathogen associated molecular pattern rec-
ognition systems are already functional at one day post fertiliza-
tion, zebrafish embryos and larvae are highly suitable for rapid
screening of disease progression up to the stage that feeding be-
comes necessary and ethical constraints become apparent [85].
For infection studies a common route of infecting zebrafish em-
bryos is the injection of the pathogen into the caudal vein of
1 day old embryos [7]. This method is relatively labour-intensive
and although it has been successfully used for drug screens [86]
it compares to cellular screening technologies as a low throughput
technique, leading to major bottlenecks in drug discovery. Since
infection by immersion in most infection models is not an effective
alternative [96], we sought to achieve a reliable high-throughput
automatic injection system, drastically reducing the man-hour
requirement while vastly increasing the number of reproducibly
infected embryos. As shown by Carvalho et al. [15] and Veneman
et al. [97] we have successfully used robotic microinjection tech-
nology for screening bacterial proliferation during the first 5 days
of larval development. In these studies the COPAS technology men-
tioned above was used to monitor bacterial proliferation. Carvalho
et al. [15] have also shown that this high-throughput injection
method, by its versatile applicability in small high safety flow cab-
inets, can be used for the study of infection by dangerous human
pathogens such as Mycobacterium tuberculosis owing to the fact
that this bacterial species can survive within macrophages of zeb-
rafish larvae.
1.3. Applications of microinjection for studies of cancer progression
The zebrafish is increasingly used as a model for the study of
cancer progression and metastatic potential of tumor cells
[3,31,48,59,68,100]. The optical transparency of zebrafish larvae
has permitted novel insights into mechanisms underlying tumor
cell migration and the role of host recognition factors that are
highly useful for the study of human cancers [32,32,39,90]. High-
throughput methodologies have been applied in oncologic small
molecules screens in zebrafish [80,88,89,93], however, testing
has mainly been performed by addition of potential therapeutic
drugs to the swimming water of zebrafish as microinjection of
drugs has been hampered by technical limitations in the through-
put level. However, the use of artificial carriers that can be used for
slow release of drugs has been shown to be highly applicable for
future screening for efficacy or toxicity of therapeutics in zebrafish
[69]. Especially promising for disease studies in general is the use
of photodegradable biogels that can be used for controlled release
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sively applied for xenografting of cancer cells and non-transformed
cells, including stem cells [22,29,38,39,48,50,63,83,87]. It was
shown that many cancer cell types from mammalian origin can
survive for extended periods during larval development and that
proliferation and spreading can be monitored using automated
methods [34]. Clonal zebrafish lines which allow serial transplan-
tations of tumor cells from one fish to another without detrimental
gamma-irradiation or usage of immunosupressants can be used for
studying the behaviour of xenografted tumor cells in zebrafish
after an adaptive immune system has developed [62]. Various
studies have explored the possibilities for injecting cancer cells
in different tissues of zebrafish embryos or larvae during different
developmental stages. For instance injection of mammalian cancer
cells into the yolk, cardinal vein, duct of Cuvier, or hindbrain can
lead to efficient proliferation and spreading, depending on which
tumor cell line is used [22,29,34,38,39,50,83]. It has been indicated
that automatic robotic injection of tumor cells can also be per-
formed using robotic technology [15]. In this paper we provide
methods for automated injection of tumor cells in early pre-gastru-
lation stage zebrafish embryos and we show how this method can
be used for screening of cancer cell proliferation and spreading.
2. Methodology
2.1. General injection and screening protocol
Robotic microinjection was performed using needles from the
company Qvotek (Table 1). For comparisons we have used borosil-
icate glass capillary needles [7], made with a Harvard Apparatus
needle puller. Although these needles are perfectly suitable for
manual injection, the commercial needles were needed for robotic
injection in order to obtain highly reproducible results. For DNA,
morpholino and bacterial injections, needles with an inner tip
diameter of 10 lm were used, whereas for cancer cell injections
needles with an inner diameter of 20 lm were used. For injection
we used a specially designed grid that has been described previ-
ously by Carvalho et al. [15]. Zebrafish embryos were placed on a
1% agarose covered grid with a featured honeycomb pattern con-
sisting of 1024 hemi-spherical wells (1.3 mm diameter), except
for DNA injection where a new grid with 9 blocks of 100 wells
was used. The embryo grid was placed in a motorized stage cou-
pled to a controller and a motorized micro-manipulator. The
loaded injection needle was placed in the Injectman II (Eppendorf).
The injection height was set using a new precise z-calibration unit
(Life Science Methods BV), consisting of a prism fixed next to a hole
in the multi-well plate holder which offers a side-view of the nee-
dle (Qvotech) when lowered into this hole. For calibration the hole
is centered above the lens and a needle is lowered into the hole un-
til a dot appears on the screen. The user then clicks on the dot toTable 1
Specifications of capillaries (Qvotek, Mississauga, Canada) for robotic intrayolk
injection of zebrafish embryos.
Parameter Value
Start capillary Borosilicate 100 mm x 1 mm O.D.
(0,75 mm I.D.)
Tip end Beveled and heat-formed spike
Tip angle No
Orientation of tip opening Top
Flexibility of tip Rigid
Taper Short
Inner tip diameter, bacterial
injections
10 lm
Inner tip diameter, tumor cell
injections
20 lmcenter the needle with a precision of smaller than 4 pixels
(10 lm). Subsequently, the prism is centered above the lens and
the needle is moved to the focal plane of the prism. On the screen
a side view of the needle appears and the user clicks on the tip of
the needle to calibrate the needle height with equal precision. This
3D datum position is then used to calculate the injection point in
the egg with an accuracy of 10 lm in 3D. All components were
connected to the controlling computer (linutop, www.linu-
top.com), which was equipped with a software control program
written in python (Life Science Methods BV). For subsequent
high-throughput screening we made use of the COPAS-XL (Union
Biometrica) as described previously [15,97]. For post sorting
analysis of the data we have developed a new script, written in
the software package Perl, which can show the distribution of fluo-
rescence pixels in the body of zebrafish larvae as demonstrated
with data shown in the bacterial infection section (Figs. 1 and 2).
2.2. Injection of DNA
We injected a DNA construct containing a GFP fusion gene (beta
actin promoter-NLSmCherry-IRES-GFP) in the Gateway Tol2 vector
together with Tol2 transposase RNA using standard protocols
[51]in the middle of the yolk before the first cell-stage. This re-
sulted in fluorescence outside of the yolk at 6 days post implanta-
tion (DPI) in 15% of the cases (results not shown). High-throughput
injection in combination with subsequent COPAS sorting of fluo-
rescent larvae could make up for this low yield. However, since it
has been reported that DNA-constructs should be injected close
to or inside the first cell of the embryo proper to improve integra-
tion efficiency, an alternative semi-automated solution was devel-
oped. A new macro was developed to move the stage to an egg,
show an image of the egg, after which the user determines the best
injection spot. The pointer is moved to this spot and a mouse-click
initiates an injection. After the injection the macro moves the robot
to the next egg. Injections were performed close to the cell and in
the first cell, and yield was measured as number of embryos show-
ing fluorescence outside the yolk divided by the total number of in-
jected embryos at 6 DPI using a Leica MZ16FA stereo fluorescence
microscope. To reduce the delay between different sets of injec-
tions, a new grid was used featuring nine blocks of 100 wells. Using
a scalpel the agarose grid was cut after injections and the blocks
were harvested separately. The yield of semi-automated DNA
injection directed just under the first cell is shown in Table 2 dem-
onstrating a yield (at 6 DPI) that is similar to manual injection
when COPAS sorting is used (Table 2), however the throughput
(<5 s per egg) as well as simplicity (one mouse click) of semi-auto-
mated injection is far greater. The semi-automated injections of
DNA will be fully automated for future applications by recording
a database of images together with their best injection spot. Auto-
mated image recognition can be used to find the best correlating
image from this database. As such we expect to achieve a speed
of 1500 eggs per hour for DNA constructs. In order to achieve this
we still need to optimise the lighting as we currently use ambient
light.
2.3. Injection of bacteria and screening for bacterial infection
We previously published the development of an automatic
injection system for yolk injection in zebrafish embryos [15]. In
brief, at 2 h post-fertilization (hpf) or 4 hpf, zebrafish embryos
were placed in the 1024 wells agarose grid and injected within half
an hour. The system was successfully applied to M. marinum and
M. tuberculosis injection in zebrafish embryos, which serve as a
promising model for anti-tuberculosis drug screening [15]. In addi-
tion we have also applied this method for injection of S. epidermidis
at 2 hpf. The results show that the number of injected bacteria is
Fig. 1. Progression of the bacterial burden in whole embryos (A) or the tail section of the same embryos (B). Groups of at least 50 embryos were analysed between 3 DPI to 6
DPI and red fluorescent signal was measured and shown in the graphs as mean ± S.E. Different letters indicate statistical significant differences between embryos of the same
treatment (p < 0.05). ns, no significant differences.
Fig. 2. Quantification of fluorescence intensity of S. epidermidis injected embryos using the COPAS XL and PERL macro. The bar graph represents the average fluorescence
intensity from 4 biological replica’s (70 embryos per group) in the tail and the entire body at 5 DPI (error bars represent SEM).
Table 2
Comparison of different DNA injection methods. Fully-automated and semi-automated methods show 2–3 times higher success rate per minute compared to manual methods
(last column). COPAS sorting at 1 DPI can almost double (79% vs 43%) the chance of DNA expression at 6 DPI.
Method Total inj. % DNA-expressing







Manual injection (in the cell) not sorted at 1DPI 63 79 38 25 2.5 1.0
Manual injection (yolk center) not sorted at 1DPI 120 83 29 15 8.0 2.3
Full-automated (yolk center) selected using COPAS at 1DPI 524 35 52 15 34.9 5.2
Semi-automated injection (close to the cell) not sorted at 1DPI 223 25 43 20 11.2 4.1
Semi-automated injection (close to the cell) selected using COPAS at 1DPI 223 25 79 20 11.2 2.1
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PAS analysis. We also have shown that COPAS analysis can reliably
reproduce counting by bacterial plating thereby providing a versa-
tile method for quantification of bacterial proliferation [97]. In
addition to the capacity of the COPAS technology to sort embryos
based on pre-set fluorescence or optical density properties, we
show that it can also be useful for quantification of the distribution
of injected particles using a specially designed Perl script. To
demonstrate this we have analyzed the data obtained from aM. marinum infection experiment in which the injected larvae were
analyzed for bacterial spreading in the larva in the presence or ab-
sence of the antibiotic rifampicin. Zebrafish embryos between 16
and 64 cell stage were injected with 40 CFUs (colony forming
units) of M. marinum strain E11 expressing the fluorescent protein
mCherry. Three days post-injection larvae were analysed and pre-
sorted using the COPAS XL (Union Biometrica). Pre-sorting settings
were established in order to ensure a homogenous group of
embryos presenting moderate infection levels, discarding
250 H.P. Spaink et al. / Methods 62 (2013) 246–254non-infected and highly infected embryos. Sorted larvae were trea-
ted with either 0.2% DMSO (control) or 200 lM rifampicin. Em-
bryos were treated and infection levels were analyzed with
COPAS XL for three days. The resulting optical density and red fluo-
rescence profiles were analysed with a custom made script. The
script reads the optical density and the red fluorescence profiles
from a larva. It then divides both profiles in two and sums the opti-
cal density values and red fluorescence values for each half. The
anterior half of the larvae is optically more dense compared to
the posterior half and will have a higher sum. The lower optical
density sum will determine the posterior half of the profile. The
sum of the red fluorescence values for this half is the tail fluores-
cence and the sum of both halves is the total fluorescence. This al-
lows us to analyse infection levels either in the whole larvae or in
the tail section. The results (Fig. 1) show that bacteria can be de-
tected with high sensitivity in the tail part of the larvae. We have
also used this method for reanalysis of the previously published
data set for S. epidermidis injection that was used for yielding a ref-
erence transcriptome database [97]. The results (Fig. 2) show that
injected staphyloccoci massively spread into the tail part starting
two days after injection providing quantitative data that further
support the images from confocal laser scanning microscopy [97].2.4. Injection of bacteria in combination with antisense morpholinos
The conventional procedure of gene function analysis during
bacterial infection in zebrafish embryos is to inject morpholino oli-
gonucleotides at 1–2 cell stage into yolk followed by bacterial
injection into the caudal vein after the onset of blood circulation.
This method is well-established but time consuming and low-
throughput [81]. The labour intensity of such injections can be
overcome by carrying out co-injection of morpholino and bacteria
into the yolk of 1–2 cell stage zebrafish embryos using the auto-
mated injection system. This experimental setup was first tested
using a morpholino oligonucleotide (GeneTools, Oregon, USA) de-
signed against the transcription factor Pu-1 (Spi1) that blocks mye-
loid development [15]. These results confirmed the methodology
and prompted us to investigate the function of more specific im-
mune regulatory factors such as a follow up study on myeloid dif-
ferentiation factor 88 (Myd88), an adaptor protein in Toll-like
receptor signalling that has been studied by gene knock-down
and gene knock-out analysis in zebrafish embryos, and shown to
be involved in proinflammatory innate immune response to micro-
bial infection [81,95]. For this, one nanoliter of myd88 morpholino
at 1.6 mM concentration was co-injected with 40 CFUs of M. mar-
inum at the 1–2 cell stage into the yolk of zebrafish embryo. Anal-
ysis of the fluorescence profile of 5 days post-injected embryosFig. 3. Automatic co-injection of antisense morpholino and bacteria into yolk.
Increased bacterial burden was measured using the COPAS system in myd88 and
control morphants at 5 DPI following co-injection of Mycobacterium marinum with
myd88 morpholino into 1–2 cell stage zebrafish embryos. Asterisk indicate
significant difference (⁄⁄⁄p < 0.0001) tested by unpaired t-test.using the COPAS technology showed an increased bacterial burden
in the morphant group compared to the control group due to
knock-down of this gene (Fig. 3). These results mimic the already
published infection studies with Myd88 knock-down, confirming
that automatic yolk co-injection of morpholino and bacteria is
capable of creating reproducible results for morpholino screens
in a high-throughput manner.2.5. Tumor cell implantation and screening for proliferation and
spreading of cancer cells
2.5.1. Robotic injection of tumor cells
In manual injection experiments various tumor cell lines were
shown to be highly different in their capacity to proliferate and
spread into the entire zebrafish body after injection into the yolk
of pre-gastrulation stage embryos. Pilot experiments using the
injection robot with the highly aggressive osteosarcoma cell lines
SJSA-1 (American Type Culture Collection , ATCC) and osteosar-
coma line L2792 [13] showed a massive proliferation and strong
spreading of fluorescent cells in the tail at 3 days post injection into
the yolk at the 256-cell stage (Fig. 4). For further implantation as-
says shown in this paper, human prostate cells (PC3 and LNCap)
and a highly angiogenic melanoma line (Mel57-VEGF) were used.
The latter line was chosen because a stably transfected line was
available that yielded a bright fluorescent signal that could be mea-
sured reproducibly at low cell counts using the COPAS technology.
In order to investigate the dissemination of tumor cells in zeb-
rafish embryos, we developed an optimal setup for the establish-
ment of a high-throughput xenograft model using the automated
injection system. Cells were cultured as previously described i.e.
in RPMI-1640 medium (Sigma Aldrich) supplemented with fetal
bovine serum to a final concentration of 10%. Cells were subdivided
2–3 times a week at ratio of 1:5–1:10. Cultures were renewed
every 8 passages. During subdividing care was taken that single
cells were passed so no aggregates have formed. For transplanta-
tion, cells with 75–80% confluency should be used as they tend
to clump less then more confluent cell cultures. For detection ofFig. 4. Confocal laser scanning analysis of 5 days old larvae injected with
osteosarcoma cell line SJSA-1 at the 256 cell stage. For these studies a transgenic
zebrafish Tg (Fms:Gal4, UAS:mCherry) was used [36]. The figure shows a z-series
projection of a part of the tail area with the mCherry signal shown in orange and the
DiI of a multitude of cancer cells signal shown in red. Blue color represents
autofluorescence.
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were labeled using the following protocol: T75 flask with cells
reaching 80% confluency were gently but quickly rinsed with
1 ml Trypsin–EDTA. For getting cells into suspension, cells were
covered with 0.5 ml of Trypsin–EDTA and incubated for 2–5 min
at 37 C. Trypsination was stopped by adding 1 ml of PBS with
10% FCS and cell lumps were broken by gentle pipetting up and
down. From this step no visible cell aggregates should be observed.
Single cells were pelleted by centrifugation at 100g for 4 min in a
2 ml Eppendorf tube. Pellets were resuspended in 0.5 ml PBS with
CM-DiI (InVitrogen) incubated first at 37 C for 5 min and later at
4 C for an additional quarter of an hour. After this step, cells were
centrifuged again at 100g for 4 min, washed once in 0.5 ml PBS and
counted. Finally cells were resuspended in 14% PVP to a final con-
centration of minimum 200 cells per microliter. Prior to injection,
the labelled cells were kept at 34 C and implanted within 3 h.
Transgenic cells were treated in a similar way but the step related
to incubation with a dye was omitted. As a control, fish were in-
jected with 14% PVP. Due to the size of tumor cells, the suspension
was loaded into glass capillary needles with bigger opening (Qvo-
tech, 20 micron, Table 1). Up to 5 nl volume with minimum 400
cells were implanted using the robotic injector. Successfully in-
jected embryos (around 80–90% rate) were either sorted manually
under a fluorescence stereoscope (Leica) or sorted by the COPAS
XL. Zebrafish embryos were maintained in groups of 50 in a Petri-
dish with 20–25 ml egg water and kept at 34 C until 6 DPI. Using a
Tg (fli:GFP) endothelial reporter transgenic zebrafish line with fluo-
rescent vasculature [49], we found that PC3 and LNCap cells trans-
planted robotically behaved in the same way as manually
transplanted cells [34]. The first clearly disseminated fluorescent
tumor cells were observed at 5 DPI in the caudal vein, and also
in other small vascular in the eye and intersegmental vesselsFig. 5. Automatic injection of tumor cells into zebrafish embryos resulted in tumor d
fluorescent cell tracker CM-DiI labeled LNCap cells disseminated to the tail vascular of a 7
a 20 dry objective.(Fig. 5). These experiments showed several important technical as-
pects of the microinjection procedure. High concentration of PVP
prevented cell clumping and needle clogging. However, as highly
concentrated PVP is very viscous, it is difficult to work with. For
cells that are kept in suspensions, lower concentration of PVP will
be sufficient (e.g. 2%). It is also important to note that cell dissem-
ination has only been observed when the number of implanted
cells reached at least 400. When lower numbers of cells were im-
planted into an early embryo, even highly aggressive cells did
not migrate out of the yolk.
2.5.2. Confocal screening and tumor cell dissemination
Taking advantage of the transparency of zebrafish larvae, we
performed high-resolution confocal microscopy laser scanning
imaging to characterize the dissemination of injected tumor cells
in the case of the PC3 and LNCAP cell lines (500 cells injection).
It is known that leukocytes contribute to different steps of tumor
progression [39,77,82]. In order to investigate the role of embry-
onic myeloid cells in cancer cell spreading or killing of cancer cells,
whole-mount L-plastin immunohistochemistry was carried out as
described [56]. Antibodies and dilutions were used as follows: L-
plastin rabbit anti-zebrafish primary antibody (provided by Dr.
Huttenlocher), was diluted 1:500 and the secondary antibody
(Alexa 568 anti-rabbit, Invitrogen) was used at a 1:200 dilution.
At 6 DPI, confocal imaging of fixed larvae revealed the presence
of labeled cells in the vascular system, indicating that injected
human tumor cells survived and disseminated outside the yolk-
(Fig. 6). Noteworthy, we also detected that labeled tumor cells
were accompanied by a leukocyte population at various positions
in the tissue-(Fig. 6), suggesting that myeloid cells have a role in
cancer cell recognition. In future studies we will study whether dif-
ferences in dissemination are correlated with the aggressiveness ofissemination. (A and B) confocal z-series projection and (C and D) bright-field of
day-old larva. Images were acquired using a Leica TCS SPE confocal microscope with
Fig. 6. Confocal screening of tumor cell dissemination in zebrafish embryos. PC3 and LNCap (red color) injected in embryos showed clear dissemination from the original
implantation site at 6 DPI. Leukocytes (in blue) associated with tumor cells are visible at the dissemination site with the vascular system in green (this signal is omitted in the
in bottom panels). Two representative images are shown of embryonic leukocytes associated with fluorescent tumor cells at the caudal vein. Images were acquired using a
Leica TCS SPE confocal microscope with a 20 dry objective.
252 H.P. Spaink et al. / Methods 62 (2013) 246–254tumor cell type. For this we will use a combination of the auto-
mated injection system together with published high-throughput
imaging technologies [34] to screen for the malignancy of many
different mammalian cancer cell lines in the zebrafish embryo
model at higher throughput levels than previously established.Fig. 7. Proliferation of automatic injected Mel57 cells in zebrafish embryos. Total
fluorescent signal intensity quantifies the increase of tumor cell number in the
injected embryos over 6 days. The sample size for each experiment was >400
embryos. More than 150 successfully injected embryos were sorted out at 1DPI.
Final survival rate was >80% at 6DPI.2.5.3. COPAS screening for tumor cell proliferation
To demonstrate the survival rate and proliferation of injected
tumor cells in zebrafish embryos, we employed a stably transfec-
ted melanoma cell line Mel57-VEGF expressing EGFP, [84] in our
robotic injection system. A large set of embryos were injected with
Mel57-EGFP cells (400 cell/embryo) at 2 and 4 hpf. The injected
embryos were immediately run through the COPAS system to
determine the total level of green fluorescence, which represents
the injection load. The embryos were subsequently sorted with
the following parameters: optical density threshold (extinc-
tion) = 390 mV (COPAS value: 20), minimum time of
flight = 280 ms (COPAS value: 700), red photomultiplier tube
(PMT) voltage = 0 V, green PMT voltage = 600 V, yellow PMT volt-
age = 0 V, fluorescent density threshold = 800. Successfully injected
embryos were followed with the COPAS system until 6 DPI.
Combination of COPAS profiling and epifluorescence/bright-
field imaging revealed significant tumor cell proliferation in the in-
jected embryos (Fig. 7). At the first day after injection, the fluores-
cent signal of tumor clusters slightly dropped, suggesting a
decrease of live cells due to the implantation process. At 6 DPI,
the average signal per larva had significantly increased, and was al-
most 2-fold higher than than at 1 DPI (Fig. 7). These results illus-
trated the ability of COPAS to accurately quantify the number of
tumor cells in zebrafish embryos. This shows that the combination
of the automatic injection and COPAS sorting system provides apowerful in vivo platform for the investigation of human cancer
proliferation, which in turn highly facilitates the discovery and
screening of anti-cancer compounds directed at targets from the
Table 3
Overview of robotic injection applications. For details on the microbial robotic injection variables tested we also refer to Carvalho et al., 2011 [15] and Veneman et al., 2013 [97].
Robotic injection application Variables tested Limiting factors
DNA  Position of injection
 COPAS screening
 Higher accuracy of injection site will limit speed
Morpholinos  Combination with microbial injection  Morpholinos have to be injected as early as possible
Microbes  Different types of microbes (e.g.
Mycobacteria and Staphylococci)
 Embryonic stage of injection
 Microbial escape from yolk
 There is a delay period before bacteria from yolk will be exposed to cellular
immune responses (e.g. phagocytosis)
 For whole organism screening there will be background fluorescence from
microbes in the yolk
Cancer cells  Cancer cell types
 PVP concentration
 Spread to different body parts
 Embryo survival rates
 Clumping of cells that will clog needles
H.P. Spaink et al. / Methods 62 (2013) 246–254 253implanted cells and the recipient host. Based on these results we
have recently started with follow up studies using our methods
of xenografting with many other cancer cell lines aimed at obtain-
ing mechanistic insights in the spreading of cancer cells through
the zebrafish body. These studies already have indicated that using
this methodology new knowledge can be obtained in proliferation
and metastatic behaviour of Ewing’s sarcoma cells (manuscript in
preparation). This is of clinical relevance since at the time of diag-
nosis 25% of Ewing’s sarcoma patients, predominantly children
and young adults, present with metastatic disease and a poor sur-
vival prognosis. In case of recurrence of the disease, overall survival
rates are as low as 10–20%. Although the causative underlying
defect is known, there are currently no reliable treatment strate-
gies for this malignant bone tumor. Therefore, high-throughput
screening is greatly needed for rapid pre-clinical drug screens for
this type of tumor.
3. Conclusions
The provided methods for robotic microinjection of DNA, mor-
pholinos, bacteria and cancer cells in zebrafish embryos enables
the generation of an abundance of reproducibly treated living test
models. In Table 3 we present a summary of variables that we have
tested with our developed technology. We have shown that this
technology benefits optimally from many new high-throughput
screening methods. These methods are not only applicable to the
disease models highlighted in this paper, i.e. cancer and infectious
disease, but are widely applicable to studies that benefit from the
use of small transparent zebrafish larvae. We anticipate that our
technology is also applicable to other fish models. For instance
the use of carp fish, which are easy to culture and have a clutch size
of hundred thousands of eggs in one spawn, would be extremely
useful for screens in larvae at ultra high-throughput level [1]. We
have recently generated a draft genome of the European common
carp (Cyprinus carpio carpio) showing a striking gene similarity
with the zebrafish, but, a much higher compactness of the genome,
making it highly interesting for further comparative studies with
zebrafish at the genetic level [41]. In our own research we will con-
tinue to use zebrafish and other fish species for applications in dis-
ease studies, but, we will also give more attention to the
applicability of our methodology for toxicology research in zebra-
fish [30]. This is because we believe that the combination of
screens for potential new therapeutics will benefit greatly in speed
by a combination with toxicology approaches. In the near future
the use of our microinjection technology will also be used for de-
tailed drug RP/KD studies that should give indications on the trans-
latability of drug treatment effects and might suggest protocols for
optimized drug administration. For this the injection of synthetic
slow or controlled release vehicles in combination with highly sen-
sitive detection of compounds using mass spectrometry will be
highly valuable [69–71,76].Acknowledgements
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